Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
暂无分享,去创建一个
Jack Cuzick | Lisa McShane | Christos Sotiriou | Mitch Dowsett | Matthew Ellis | Daniel F Hayes | Roger A'Hern | M. Ellis | J. Cuzick | T. Nielsen | C. Sotiriou | M. Dowsett | S. Paik | L. McShane | G. Viale | J. Bartlett | F. Penault-Llorca | M. Regan | D. Hayes | J. Salter | I. Smith | R. A’Hern | J. Zujewski | J. Hugh | T. Lively | R. C. Coombes | Torsten O Nielsen | Judith C Hugh | Giuseppe Viale | Ian E Smith | Tracy Lively | Frederique Penault-Llorca | Janine Salter | Soon Paik | Jo Anne Zujewski | John Bartlett | N Lynn Henry | Meredith Regan | R Charles Coombes | Ljudmila Prudkin | N. L. Henry | Ljudmila Prudkin
[1] M. Boon. Microwave-antigen retrieval: the importance of pH of the retrieval solution for MIB-1 staining. , 1996, European journal of morphology.
[2] D. Arber. Effect of Prolonged Formalin Fixation on the Immunohistochemical Reactivity of Breast Markers , 2002, Applied immunohistochemistry & molecular morphology : AIMM.
[3] Thomas Rüdiger,et al. Inter‐laboratory and inter‐observer reproducibility of immunohistochemical assessment of the Ki‐67 labelling index in a large multi‐centre trial , 2002, The Journal of pathology.
[4] Charles M. Perou,et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.
[5] Mitch Dowsett,et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.
[6] A. Chan,et al. The contribution of bifunctional SkipDewax pretreatment solution, rabbit monoclonal antibodies, and polymer detection systems in immunohistochemistry. , 2007, Archives of pathology & laboratory medicine.
[7] G. Hortobagyi,et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Ellis,et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. , 2003, Cancer research.
[9] J. Olson,et al. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. , 2009, Journal of the American College of Surgeons.
[10] J. Forbes,et al. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] M. Dowsett,et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer , 2010, Breast Cancer Research.
[12] C. Perou,et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] S. Teutsch,et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group , 2009, Genetics in Medicine.
[14] W. Sauerbrei,et al. Confidence intervals for the effect of a prognostic factor after selection of an ‘optimal’ cutpoint , 2004, Statistics in medicine.
[15] B. Calvo,et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Mitch Dowsett,et al. Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. , 2011, Journal of the National Cancer Institute. Monographs.
[17] Robin L. Jones,et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer , 2009, Breast Cancer Research and Treatment.
[18] Jingqin Luo,et al. Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics , 2008, Journal of the National Cancer Institute.
[19] Johannes Gerdes,et al. The Ki‐67 protein: From the known and the unknown , 2000, Journal of cellular physiology.
[20] J. Olson,et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. R. Reeves,et al. Outcome and human epidermal growth factor receptor (HER) 1–4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling , 2004, Breast Cancer Research.
[22] S. Pilotti,et al. Immunoreactivity to MIB‐1 in breast cancer: methodological assessment and comparison with other proliferation indices , 1997, Cell proliferation.
[23] K. Gelmon,et al. Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.
[24] M. Dowsett,et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] Robin L. Jones,et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer , 2009, Breast Cancer Research and Treatment.
[26] J. Hendricks,et al. Effect of fixation time and microwave oven heating time on retrieval of the Ki-67 antigen from paraffin-embedded tissue. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[27] J. Cuzick,et al. Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score – Results from TransATAC. , 2009 .
[28] M. Dowsett,et al. Comparison of the Short-Term Biological Effects of 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17β-diol (Faslodex) versus Tamoxifen in Postmenopausal Women with Primary Breast Cancer , 2001 .
[29] F. Penault-Llorca,et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] D. Rimm,et al. Long-term preservation of antigenicity on tissue microarrays , 2004, Laboratory Investigation.
[31] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[32] R. Gelber,et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. , 2008, Journal of the National Cancer Institute.
[33] S. Lakhani,et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer , 2004, British Journal of Cancer.
[34] Quynh-Thu Le,et al. Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma , 2010, Clinical Cancer Research.
[35] D. Rimm,et al. Quantitative Assessment Shows Loss of Antigenic Epitopes as a Function of Pre-analytic Variables , 2011, Laboratory Investigation.
[36] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.
[37] R. Bast,et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] J. Bartlett,et al. Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma , 2009, Histopathology.
[39] J. Forbes,et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.
[40] W. McGuire,et al. Evaluation of a modeling system for S-phase estimation in breast cancer by flow cytometry. , 1987, Cancer research.
[41] M. Ellis,et al. Abstract S1-1: Final Analysis of NCIC CTG MA.27: A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Hormone Receptor Positive Primary Breast Cancer , 2010 .
[42] M. Dowsett,et al. Comparative validation of the SP6 antibody to Ki67 in breast cancer , 2010, Journal of Clinical Pathology.
[43] D. Rimm,et al. Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.
[44] H Stein,et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.
[45] Johannes Gerdes,et al. Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.
[46] C Caldas,et al. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. , 2008, Breast.
[47] M. Dowsett,et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] M. Dowsett,et al. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[49] T. Powles,et al. Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast Cancer , 2003, Breast Cancer Research and Treatment.
[50] P. Hall,et al. The relevance of antibody concentration to the immunohistological quantification of cell proliferation‐associated antigens , 1993, Histopathology.
[51] M. Tubiana,et al. The long‐term prognostic significance of the thymidine labelling index in breast cancer , 1984, International journal of cancer.
[52] Mitch Dowsett,et al. Proliferation marker Ki-67 in early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.